NuVasive® is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the third largest medical device company in the $8.2 billion global spine market. NuVasive’s principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform’s lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 90 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.
Company Growth (employees)
NuVasive was founded in 1997 and is headquartered in San Diego, US
NuVasive Office Locations
NuVasive has offices in San Diego, Memphis, Columbia, Fairborn and in 9 other locations
San Diego, US (HQ)
7475 Lusk Blvd
Amstelveen, NL
14 Grutterij
Milano, IT
32 Via Giacomo Watt
Chūō Ku, JP
銀座第１３金井ビル
Elstree, GB
The Waterfront
Bremen, DE
75 A Contrescarpe
Kew, AU
620 High St
Aliso Viejo, US
100 101 Enterprise
Fairborn, US
1 Herald Square
Columbia, US
250 10420 Little Patuxent Pkwy
Memphis, US
101 4670 E Shelby Dr
NuVasive Data and Metrics
NuVasive Financial Metrics
NuVasive's revenue was reported to be $962.1 m in FY, 2016
$, USD
Revenue (FY, 2016) | 962.1 m |
Revenue growth (FY, 2015 - FY, 2016), % | 19% |
Gross profit (FY, 2016) | 722 m |
Gross profit margin (FY, 2016), % | 75% |
Net income (FY, 2016) | 35.4 m |
Market capitalization (23-Jun-2017) | 3.9 b |
Closing share price (23-Jun-2017) | 76.9 |
Cash (31-Dec-2016) | 153.6 m |
NuVasive's current market capitalization is $3.9 b.
| $, USD | FY, 2013 | Y, 2014 | Y, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 685.2 m | 762.4 m | 811.1 m | 962.1 m |
Revenue growth, % | 11% | 6% | 19% | |
Cost of goods sold | 180.5 m | 182.4 m | 194.5 m | 240.1 m |
Gross profit | 504.7 m | 580.1 m | 616.6 m | 722 m |
Gross profit Margin, % | 74% | 76% | 76% | 75% |
Operating expense total | 471.6 m | 561.9 m | 477.6 m | 598.5 m |
EBIT | (13.6 m) | |||
EBIT margin, % | (2%) | |||
Interest expense | 27.2 m | 27.9 m | 29.1 m | 40.5 m |
Interest income | 755 k | 968 k | 1.6 m | 1.1 m |
Pre tax profit | 9.8 m | (11.2 m) | 112 m | 64.7 m |
Income tax expense | 2.8 m | (6.3 m) | (46.7 m) | (29.3 m) |
Net Income | 7 m | (17.5 m) | 65.3 m | 35.4 m |
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 102.8 m | 142.4 m | 192.3 m | 153.6 m |
Inventories | 10.9 m | 21.6 m | 8.8 m | 10 m |
Current Assets | 536 m | 705.9 m | 702.8 m | 575.4 m |
PP&E | 128.1 m | 128.6 m | 141.4 m | 181.5 m |
Goodwill | 154.9 m | 154.4 m | 154.3 m | 485.7 m |
Total Assets | 1.2 b | 1.3 b | 1.3 b | 1.6 b |
Current Liabilities | 117.2 m | 214.9 m | 99.6 m | 242.5 m |
Additional Paid-in Capital | 769.2 m | 847.1 m | 989.4 m | 1 b |
Retained Earnings | (170.2 m) | (186.9 m) | (120.6 m) | (66.9 m) |
Total Equity | 595.8 m | 648.4 m | 702.2 m | 700.5 m |
Financial Leverage | 2 x | 2.1 x | 1.8 x | 2.2 x |
| $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 7 m | (17.5 m) | 65.3 m | 35.4 m |
Depreciation and Amortization | 63.1 m | 65.8 m | 65.9 m | 102.7 m |
Accounts Receivable | (17 m) | (18 m) | (9.5 m) | (33 m) |
Inventories | (3.6 m) | (5.2 m) | 1.2 m | (5.7 m) |
Cash From Operating Activities | 97.4 m | 115.5 m | 88.7 m | 156.3 m |
Purchases of PP&E | (47.6 m) | (58.4 m) | (75.8 m) | (88.4 m) |
Cash From Investing Activities | (64.6 m) | (104.8 m) | (7.5 m) | (304.9 m) |
Long-term Borrowings | (74.3 m) | |||
Cash From Financing Activities | (52.5 m) | 30.3 m | (30.3 m) | 110.8 m |
Interest Paid | 12 m | 11.1 m | 11.1 m | 13.2 m |
Income Taxes Paid | 3.2 m | 13.6 m | 36.3 m | 23.7 m |
| $, USD | Y, 2016 |
|---|---|
Revenue/Employee | 601.3 k |
Financial Leverage | 2.2 x |
NuVasive Market Value History
NuVasive Median Salaries
Source: 31 public H-1B filings from NuVasive
